Ten years-experience of sunitinib in the treatment of advanced pan-NETs: an update on safety profile

Vivanet, Grazia; Laffi, Alice; Rubino, Manila; Spada, Francesca; Fazio, Nicola

doi:10.1080/14740338.2022.2000964

Cited by 1 publication

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SC proliferation and self-renewal in response to resistance training and muscle damage depend on the interleukin-6 (IL-6) cytokine's activation of the signal transducer and activator of transcription 3 (STAT3) [91][92][93]. Sunitinib is a multi-targeted tyrosine kinase inhibitor and a therapeutic option for treating renal cell carcinoma, gastrointestinal stromal tumors, and progressive, well-differentiated, advanced panNETs [24,94]. Sunitinib was evaluated for its efficacy in the mdx mice model of DMD, in which it demonstrated the ability to induce muscle regeneration via transient STAT3 activation [90].…”

Section: Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

The Potential Benefits of Drug-Repositioning in Muscular Dystrophies

Lambrescu¹,

Manole²,

Ceafalan³

et al. 2023

Potential Therapeutic Strategies for Muscular Dystrophy

View full text Add to dashboard Cite

Muscular dystrophies (MDs) are a complex group of rare neuromuscular disorders caused by genetic mutations that progressively weaken the muscles, resulting in an increasing level of disability. The underlying cause of these conditions consists of mutations in the genes in charge of a person’s muscle composition and functionality. MD has no cure, but medications and therapy can help control symptoms and slow the disease’s progression. Effective treatments have yet to be developed, despite the identification of the genetic origins and a thorough knowledge of the pathophysiological alterations that these illnesses induce. In this scenario, there is an urgent need for novel therapeutic options for these severe illnesses, and drug repositioning might be one feasible answer. In other words, drug repositioning/repurposing is an accelerated method of developing novel pharmaceuticals since the new indication is based on previously accessible safety, pharmacokinetic, and manufacturing data. This is particularly crucial for individuals with life-threatening illnesses such as MDs, who cannot wait for a conventional medication development cycle. This chapter aims to review the challenges and opportunities of drug-repositioning in a variety of MDs to establish novel treatment approaches for these incurable diseases.

show abstract